-
Porton Pharma Solutions’ Porton Advanced Partners with Eureka Therapeutics on T-Cell Therapies
•
China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions’ subsidiary Porton Advanced, a specialist in advanced therapy medicinal products (ATMPs), has formed a partnership with US-based biotech firm Eureka Therapeutics, Inc. The collaboration focuses on the global clinical development of T-cell therapies, with financial details remaining undisclosed. Eureka Therapeutics’…
-
Menarini Group Partners with VisualDx to Enhance BPDCN Identification Using AI/ML Tools
•
Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has formed a partnership with US-based VisualDx. This alliance aims to enhance the identification of individuals who may have blastic plasmacytoid dendritic cell neoplasm (BPDCN) by introducing artificial intelligence/machine learning (AI/ML) tools. Understanding BPDCNBPDCN is an aggressive orphan hematologic malignancy with…
-
Sanofi to Acquire DR-0201 for $600 Million to Advance Myeloid Cell Engager
•
Sanofi (EPA: SAN, NASDAQ: SNY) announced plans to acquire DR-0201, a bispecific myeloid cell engager (MCE) targeting CD20, through the acquisition of its developer, Dren Bio, Inc. The deal underscores Sanofi’s commitment to expanding its portfolio in autoimmune diseases with a novel therapeutic approach. Deal StructureSanofi will pay an upfront…
-
Kexing Biopharm and Hinova Forge Alliance to Expand Global Market Reach
•
China-based Kexing Biopharm Co., Ltd. (SHA: 688136) announced this week a strategic alliance with compatriot firm Hinova Pharmaceuticals Inc. (SHA: 688302) to jointly explore and develop overseas markets for their collaborative products. Collaboration DetailsThe partnership between Kexing Biopharm and Hinova Pharmaceuticals is designed to leverage their combined strengths in oncology…
-
Paratek Pharmaceuticals to Acquire Optinose for $330 Million
•
Paratek Pharmaceuticals and Optinose, Inc. (NASDAQ: OPTN) announced a definitive merger agreement on March 19, 2025. Under the terms of the agreement, Paratek will acquire Optinose, including its approved product XHANCE (fluticasone propionate), an innovative drug-device combination for the treatment of chronic rhinosinusitis (CRS) with or without nasal polyps. Transaction…
-
Boji Medical’s Huasheng Transfers Glucosamine Sulfate Capsules Technology to Panlong
•
On March 20, 2025, Boji Medical Technology Co., Ltd (known as Boji Biomedicals) (SHE: 300404) announced that its subsidiary, Huasheng Pharmaceutical, has signed a technology transfer contract with Panlong Pharmaceutical. The agreement involves the transfer of technology for “Glucosamine Sulfate Capsules” from Huasheng to Panlong, with a total transfer fee…
-
Oxford BioTherapeutics Partners with Roche on Cancer Therapeutics Discovery
•
On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS: RHHBY) to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. This partnership leverages Oxford BioTherapeutics’ innovative discovery platform to identify and validate new targets for cancer therapies. OGAP-Verify Discovery PlatformOxford BioTherapeutics’ recently…
-
Servier and Black Diamond Therapeutics Ink Global Deal for BDTX-4933
•
French pharmaceutical company Servier and US-based Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) announced a strategic global licensing agreement for BDTX-4933 on March 19, 2025. This collaboration aims to advance the development of BDTX-4933, a potential best-in-class targeted therapy for solid tumors. Drug ProfileBDTX-4933 is uniquely designed by Black Diamond to…
-
Distinct Healthcare Files for Hong Kong IPO to Expand Integrated Medical Services
•
Shenzhen-based Distinct Healthcare Holdings Limited, a comprehensive medical service provider with integrated online and offline offerings, has filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. This move marks a significant step in the company’s growth strategy and capital market expansion. Company OverviewSince its inception in…
-
GE Healthcare and NVIDIA Expand Partnership to Advance Autonomous X-ray and Ultrasound Technologies
•
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) announced an expanded partnership with US-based chip giant NVIDIA (NASDAQ: NVDA) focused on the innovative application of autonomous X-ray technologies and ultrasound. This collaboration aims to transform medical imaging through artificial intelligence. Partnership DetailsThe expanded partnership will…
-
Formosa Pharmaceuticals Inks Licensing Pact with Cipla for APP13007 in 11 Countries
•
Taiwan-based Formosa Pharmaceuticals (TPE: 6838) announced a licensing agreement with India-headquartered Cipla Limited (BOM: 500087, NSE: CIPLA). Formosa is granting Cipla commercialization rights for its APP13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) in 11 countries, including India, Nepal, Sri Lanka, Bangladesh, Malaysia, Myanmar, Kenya, Nigeria, South Africa, Argentina, and Colombia. Deal…
-
Eisai Launches JPY16 Billion Tender for EcoNaviSta to Expand Dementia Care Ecosystem
•
Japan-based Eisai Co., Ltd (TYO: 4523) announced a tender offer valued at JPY16 billion (USD107 million) for all shares of EcoNaviSta Inc. (TYO: 5585), a firm specializing in dementia care solutions. This move follows a partnership forged between the two companies last July to develop an ecosystem for dementia care.…
-
Taiho Pharmaceutical to Acquire Araris Biotech for USD 400 Million, Expanding ADC Portfolio
•
Japan-based Taiho Pharmaceutical Co., Ltd. announced plans to fully acquire Araris Biotech AG, a Swiss biotech company specializing in antibody drug conjugates (ADCs). The acquisition, valued at USD 400 million with potential additional milestone payments of up to USD 740 million, is expected to close during the first half of…
-
PomDoctor Files for Nasdaq IPO to Expand Chronic Disease Management Services
•
Guangzhou-based PomDoctor Limited, a leading online medical services platform for chronic disease management, has filed for an initial public offering (IPO) with the US Securities and Exchange Commission (SEC). The company aims to list on the Nasdaq under the ticker symbol POM, marking a significant step in its growth strategy.…
-
AstraZeneca Licenses Alteogen’s ALT-B4 for Subcutaneous Cancer Therapies
•
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) has entered into a licensing agreement with South Korea-headquartered Alteogen Inc. to develop and commercialize subcutaneous versions of an undisclosed cancer drug using Alteogen’s recombinant hyaluronidase enzyme, ALT-B4. This collaboration aims to expand AstraZeneca’s oncology portfolio by leveraging Alteogen’s innovative technology for improved drug…
-
Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific
•
Switzerland-based Basilea Pharmaceutica Ltd (SWX: BSLN) announced that its antifungal Cresemba (isavuconazole), commercialized by Pfizer Inc. (NYSE: PFE), has achieved significant sales milestones in the Asia Pacific region and China. This performance has triggered a milestone payment of USD2.5 million to Basilea. Drug Profile and CommercializationCresemba, co-developed with Japan’s Astellas…
-
Accropeutics Closes RMB100 Million Series B+ Round to Advance Inflammatory Disease Pipeline
•
Accropeutics Inc., a clinical-stage biotech company with operations in New York, US, and Suzhou, China, announced the completion of a Series B+ financing round, raising close to RMB100 million (USD13.8 million). The round was led by Shenzhen Capital Group (SCGC) and included contributions from Morningside Ventures, Leader Venture Capital, and…
-
Pharmavan and Kefeng Changjian Sign Pact to Accelerate SPT-07A Development
•
Suzhou Pharmavan Co., Ltd. has announced plans to enter into a cooperation agreement with Sichuan Kefeng Changjian Pharmaceutical Technology Co., Ltd. (Kefeng Changjian) to advance the development and commercialization of the SPT-07A project. Collaboration DetailsThe agreement, based on the principle of equality and mutual benefit, aims to accelerate the speed…
-
Quantum Hi-Tech and ECNU Establish AI-Driven Drug Manufacturing Lab
•
CRO+CDMO Quantum Hi-Tech (China) Biotechnology Co., Ltd (ChemPartner, SHE: 300149) announced plans to establish an AI drug intelligent manufacturing joint laboratory with East China Normal University (ECNU), a comprehensive research-oriented university in Shanghai. This collaboration aims to set a new paradigm for school-enterprise cooperation in the field of AI-driven pharmaceutical…
-
BioCity and MSD Enter Clinical Collaboration for BC3195 and Keytruda Combination Trial
•
China-based BioCity Biopharmaceutics Co., Ltd. announced a clinical collaboration agreement with US-based giant Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK). The partnership will initiate a global Phase I/II study to evaluate the safety and efficacy of BioCity’s BC3195 in combination with MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) for patients with…
